BioMarin Pharmaceuticals financials
$59.87+0.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B |
| Gross profit | $2.50B | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B | $1.34B | $1.18B | $1.07B | $907.2M |
| Gross margin | 77.7% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% |
| Operating income | $409.5M | $474.2M | $185.8M | $39.5M | -$82.3M | -$89.1M | -$119.1M | -$171.3M | -$131.7M | -$798.5M |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | -$64.1M | $854.0M | -$23.8M | -$77.2M | -$117.0M | -$630.2M |
| Net margin | 10.8% | 15.0% | 6.9% | 6.8% | −3.5% | 45.9% | −1.4% | −5.2% | −8.9% | −56.4% |
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 |
| EBITDA | $489.0M | $570.6M | $290.2M | $141.5M | $25.7M | $16.1M | -$13.8M | -$75.6M | -$43.9M | -$102.5M |
| Operating cash flow | $828.0M | $572.8M | $159.3M | $174.2M | $296.5M | $80.9M | $43.1M | $10.9M | -$19.1M | -$170.7M |
| Free cash flow | $725.0M | $487.4M | $62.6M | $53.2M | $200.9M | -$33.4M | -$102.0M | -$133.7M | -$218.3M | -$319.1M |
| Diluted shares | 197.4M | 196.7M | 191.6M | 189.0M | 182.9M | 191.7M | 179.0M | 177.3M | 174.4M | 166.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.31B | $942.8M | $755.1M | $724.5M | $587.3M | $649.2M |
| Short-term investments | $248.9M | $194.9M | $318.7M | $567.0M | $426.6M | $416.2M |
| Total debt | $597.2M | $595.1M | $1.09B | $1.08B | $1.08B | $1.08B |
| Total assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B |
| Total liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B |
| Shareholders' equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.11B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology